Mahnoor Shahab
Research Subjects
Mahnoor Shahab has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Abu Bakar Butt
Schulich School of Medicine and Dentistry, Western University, London, Canada
1 shared publication - Andrew Mihalache
University of Toronto
1 shared publication - Anne Holbrook
McMaster University
1 shared publication - Bhavya Gandhi
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada
1 shared publication Cindy Zhang
1 shared publicationEfrem D. Mandelcorn
1 shared publication
Latest Publications
- 29 June 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (5) , 1302-1303
Efficacy and outcomes of 360° laser retinopexy versus focal laser photocoagulation for retinal detachment
- 29 June 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (5) , 1302-1303
Efficacy and outcomes of 360° laser retinopexy versus focal laser photocoagulation for retinal detachment
- Open Access
- 30 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 905-915
Major Adverse Cardiac Events with Ondansetron: A Systematic Review
Ondansetron frequently triggers medication safety alerts because of its listing as a ‘known risk’ QT interval‐prolonging medication. We aimed to summarize literature on QT‐prolongation‐related major adverse cardiac events associated with ondansetron. We searched Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Central for randomized controlled trials comparing ondansetron to placebo in adults. Major adverse cardiac events (MACE) included death, nonfatal cardiac arrest, ventricular tachyarrhythmia including torsades de pointes, seizure, or syncope. Random‐effects meta‐analyses were performed with a treatment arm continuity correction for single‐ and double‐zero event studies. We included 170 randomized trials ( n = 23,421, 70.7% female, 48.3% aged >65), 119 trials (70.0%) involving surgical patients, and 77 (45.4%) including electrocardiograms. Mean follow‐up was 10 days (SD: 21.8) (median: 1 day). Risk of bias was high for 11.8% of trials, and low for 28.8%. Only seven MACE (all deaths) were reported. Ondansetron was not associated with increased mortality ( n = 23,421, RR: 1.03, 95% CI: 0.76–1.39, I 2 = 0.0%), or arrhythmias. Lack of events precluded prespecified meta‐analyses. Further research on QT‐prolonging medications and their attributed adverse cardiac events and medication alert optimization is needed.
- 30 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 905-915
Open AccessMajor Adverse Cardiac Events with Ondansetron: A Systematic Review
Ondansetron frequently triggers medication safety alerts because of its listing as a ‘known risk’ QT interval‐prolonging medication. We aimed to summarize literature on QT‐prolongation‐related major adverse cardiac events associated with ondansetron. We searched Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Central for randomized controlled trials comparing ondansetron to placebo in adults. Major adverse cardiac events (MACE) included death, nonfatal cardiac arrest, ventricular tachyarrhythmia including torsades de pointes, seizure, or syncope. Random‐effects meta‐analyses were performed with a treatment arm continuity correction for single‐ and double‐zero event studies. We included 170 randomized trials ( n = 23,421, 70.7% female, 48.3% aged >65), 119 trials (70.0%) involving surgical patients, and 77 (45.4%) including electrocardiograms. Mean follow‐up was 10 days (SD: 21.8) (median: 1 day). Risk of bias was high for 11.8% of trials, and low for 28.8%. Only seven MACE (all deaths) were reported. Ondansetron was not associated with increased mortality ( n = 23,421, RR: 1.03, 95% CI: 0.76–1.39, I 2 = 0.0%), or arrhythmias. Lack of events precluded prespecified meta‐analyses. Further research on QT‐prolonging medications and their attributed adverse cardiac events and medication alert optimization is needed.